Baxter (BAX) is up a penny to $56.80, even after The Deal highlighted the stock as a possible takeover play. The Deal.com says BAX hasn’t hired anyone, but the co. is considered ripe for a takeout given that there are not many smaller vaccine companies left to be bought. Furthermore, BAX has modest valuation and healthy growth prospects. While shares aren’t reacting, it appears that some players in the options market are. 13K calls and 2625 puts traded, with Oct 60 and Nov 65 calls leading the flow. Data hints at non-customer buyers. Implied volatility (average) is 26 (-.7), compared to a 52-week high and low of 63 and 22.5.